Novavax names manufacturing partner for flu vaccine
Emergent BioSolutions Inc. has inked another deal with fellow Gaithersburg biotech Novavax Inc. — this time, for its seasonal flu vaccine.
The agreement means Emergent (NYSE: EBS) will develop and manufacture NanoFlu, the influenza vaccine which Novavax (NASDAQ: NVAX) successfully pushed through phase 3 clinical trials in a critical win announced March 24. It also comes just a few weeks aft er the two companies teamed up to get a COVID-19 vaccine to the clinic in the race against the pandemic.…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Sara Gilgore Source Type: news
More News: Biotechnology | Clinical Trials | COVID-19 | Flu Pandemic | Health Management | Influenza | Influenza Vaccine | Nanotechnology | Pandemics | Vaccines